Public Sector Pension investment Board decreased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 25.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,200 shares of the specialty pharmaceutical company’s stock after selling 1,400 shares during the quarter. Public Sector Pension investment Board’s holdings in Eagle Pharmaceuticals were worth $331,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mason Street Advisors LLC grew its stake in shares of Eagle Pharmaceuticals by 10.2% in the 1st quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock valued at $157,000 after buying an additional 175 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Eagle Pharmaceuticals by 74.4% in the 1st quarter. AQR Capital Management LLC now owns 34,547 shares of the specialty pharmaceutical company’s stock valued at $2,865,000 after buying an additional 14,743 shares in the last quarter. James Investment Research Inc. bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter valued at approximately $1,142,000. Thrivent Financial For Lutherans grew its stake in shares of Eagle Pharmaceuticals by 9.5% in the 1st quarter. Thrivent Financial For Lutherans now owns 4,600 shares of the specialty pharmaceutical company’s stock valued at $382,000 after buying an additional 400 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Eagle Pharmaceuticals by 7,357.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 46,084 shares of the specialty pharmaceutical company’s stock valued at $3,634,000 after buying an additional 45,466 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/public-sector-pension-investment-board-sells-1400-shares-of-eagle-pharmaceuticals-inc-egrx/1627467.html.

EGRX has been the subject of several recent research reports. Royal Bank Of Canada set a $94.00 price target on Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, July 16th. Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 10th. Piper Jaffray Companies set a $118.00 price target on Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, July 25th. BidaskClub cut Eagle Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, July 31st. Finally, ValuEngine cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $72.50.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.51 by ($0.18). The company had revenue of $50.10 million for the quarter, compared to analyst estimates of $52.52 million. Eagle Pharmaceuticals had a return on equity of 66.30% and a net margin of 39.32%. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period last year, the firm earned $0.80 EPS.

Eagle Pharmaceuticals declared that its board has authorized a stock buyback program on Wednesday, August 9th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to reacquire up to 13.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

In related news, Director Douglas L. Braunstein purchased 20,400 shares of the stock in a transaction on Wednesday, August 9th. The shares were purchased at an average price of $49.07 per share, with a total value of $1,001,028.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 19.50% of the stock is owned by insiders.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.